美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

VanEck Biotech ETF

232.02

+2.631.15%

成交量：4,581

成交額：105.91萬

市值：4.66億

市盈率：- -

高：232.10

開：230.06

低：229.59

收：229.39

52周最高：244.35

52周最低：160.91

股本：200.65萬

流通股本：200.65萬

量比：0.48

換手率：0.23%

股息：0.95

股息率：0.41%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光

TradingKey中文

安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光

TradingKey中文

再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即

再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良

瑞穗上調安進目標價至352美元

藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」

TScan Therapeutics披露：安進將終止與其研究合作及許可協議

吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光

TradingKey中文

EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標

EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌

巴克萊上調安進目標價至380美元

Assembly股價上漲，因季度營收超出預期

庫利南股價上漲，因其肺癌藥物達到晚期臨床試驗目標

MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項

數據簡報-全球製藥企業斥資數十億以擴大在美業務

Tango因季度虧損額超出預期而股價下跌

Truist因Revolution Medicines在肺癌研發管線方面的潛力而上調其目標價

市值超4800億元的藥企股價漲逾4%: 這款「癌王」突破療法要來中國了

港股異動 | 百濟神州(06160)早盤升逾4% 與Revolution Medicines達成臨床合作將加快RAS賽道開發進展

百濟神州（06160）盤初漲3.94% 與安進聯合開發及商業化的安泰適正式投入臨床使用

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BBH/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":232.024,"timestamp":1789416000000,"preClose":229.3922,"halted":0,"volume":4581,"delay":0,"changeRate":0.011472927152710503,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"盤前交易","change":2.6318,"latestTime":"09-15 04:13:25 EDT","open":230.06,"high":232.1,"low":229.5938,"amount":1059133.20111,"amplitude":0.010925,"askPrice":265.43,"askSize":100,"bidPrice":199.52,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":232.024,"sharesOutstanding":1976503,"nav":229.3061,"aum":460103384.52,"dividendRate":0.0041,"bidAskSpread":0.001038,"postHourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"volumeRatio":0.4826983051476247,"impliedVol":0.187,"impliedVolPercentile":0.376},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4826983051476247,"shares":2006503,"dividePrice":0.9513,"high":232.1,"amplitude":0.010925,"preClose":229.3922,"low":229.5938,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":232.024,"eps":0,"divideRate":0.0041,"volume":4581,"delay":0,"ttmEps":0,"open":230.06,"prevYearClose":189.2649,"prevWeekClose":229.3922,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":241.1222,"twentyDayClose":218.0411,"sixtyDayClose":188.0998},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660113478","title":"吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660113478","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660113478?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 03:17","pubTimestamp":1787167048,"startTime":"0","endTime":"0","summary":"• 得益于HIV产品组合增长加速，吉利德上调了全年销售指引。\n• 联邦法院颁布禁令阻止海外进口，以保护其核心市场份额。\n• 分析师给予“买入”评级，平均目标价为157.79美元。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118864-market-movers-gild-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","IE00BKVL7J92.USD","SG9999015978.USD","LU0320765992.SGD","LU1674673428.USD","LU2468319806.SGD","BMED","BK4578","GILD","IE00B19Z3B42.SGD","IBBQ","LU1934455277.USD","LU1066051498.USD","LU1934455863.HKD","BK4568","IBB","LU0965508806.USD","SG9999015952.SGD","BK4588","SG9999015945.SGD","LU1057294990.SGD","LU2324357040.USD","BK4583","IE0002270589.USD","LU1674673691.USD","IE00B19Z3581.USD","BK4532","BBH","LU0289739699.SGD","LU1037948541.HKD","IE00BZ1G4Q59.USD","LU0058720904.USD","BIB","LU1839511570.USD","BK4550","IE00B7SZLL34.SGD","LU0823416689.USD","LU0965509283.SGD","LU0965509101.SGD","SG9999015986.USD","TMED","LU1023059063.AUD","LU0234570918.USD","LU1934455194.USD","BK4139","LU1585245621.USD","LU1778281490.HKD","TBXU","IE00BSNM7G36.USD","LU0965509010.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660819420","title":"安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660819420","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660819420?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:16","pubTimestamp":1787163383,"startTime":"0","endTime":"0","summary":"• Argus上调安进目标价，并重申“买入”评级。\n• 第二季度财务业绩超出华尔街的营收和盈利预期。\n• 技术指标显示 MACD 买入信号及 RSI 买入条件。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118749-market-movers-amgn-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0868494617.USD","BK4139","LU1571399168.USD","IE00BJT1NW94.SGD","TBXU","LU1983299246.USD","LU0289739699.SGD","BK4533","IE00BFTCPJ56.SGD","BBH","BIB","BK4534","IE00B4R5TH58.HKD","LU0122379950.USD","IE0002141913.USD","LU2089984988.USD","PBE","BK4566","IBB","BK4599","IBBQ","IE00B2B36J28.USD","LU0320765992.SGD","IE0009355771.USD","BK4585","SG9999001440.SGD","LU1057294990.SGD","LU0889565916.HKD","LU2112291526.USD","LU2242652126.USD","LU2242646821.SGD","BK4588","PJP","LU0109394709.USD","BK4581","LU0058720904.USD","LU2468319806.SGD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105025052","title":"再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025052","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105025052?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:00","pubTimestamp":1787162410,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发的药物Pasatru已被欧洲药品管理局纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","REGN","LU2362540622.SGD","LU2468319806.SGD","LU2023250504.SGD","LU2089984988.USD","BK4588","LU0289739699.SGD","LU0823416689.USD","LU0114720955.EUR","LU2362541513.USD","LU0320765992.SGD","BBH","TBXU","IBB","LU2362541273.HKD","BK4139","LU1917777945.USD","LU0889565916.HKD","LU0053666078.USD","BK4585","LU0109394709.USD","LU2237438978.USD","LU1974910355.USD","LU0882574055.USD","LU2106854487.HKD","IBBQ","LU0058720904.USD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188134905","title":"再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良","url":"https://stock-news.laohu8.com/highlight/detail?id=1188134905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188134905?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 01:59","pubTimestamp":1787162353,"startTime":"0","endTime":"0","summary":"再生元制药公司今日宣布，其研发的新药Pasatru已获得美国食品药品监督管理局的正式批准，用于治疗成人进行性骨化性纤维发育不良。这一罕见疾病此前一直缺乏有效的治疗手段，此次获批为患者带来了新的希望。FDA的此次批准基于多项临床研究数据，结果显示Pasatru在减缓异位骨化进展方面表现出显著疗效，且安全性可控。未来，再生元制药计划进一步拓展Pasatru的适应症范围，并探索其在其他相关疾病中的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IBBQ","LU0114720955.EUR","LU1974910355.USD","LU2106854487.HKD","LU2362540622.SGD","LU0882574055.USD","BBH","LU2468319806.SGD","BK4139","LU2237438978.USD","REGN","LU0053666078.USD","LU0823434740.USD","LU2089984988.USD","LU0823416689.USD","LU0320765992.SGD","IBB","LU0889565916.HKD","LU2023250504.SGD","LU0109394709.USD","LU2362541273.HKD","TBXU","LU0823434583.USD","LU2362541513.USD","BK4585","LU1917777945.USD","LU0058720904.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660585446","title":"瑞穗上調安進目標價至352美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660585446","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660585446?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:55","pubTimestamp":1787129710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4566","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4534","IBBQ","LU0109394709.USD","LU0058720904.USD","PBE","LU0889565916.HKD","UDN","LU0122379950.USD","LU2089984988.USD","BBH","BK4585","LU0289739699.SGD","BK4581","IE0009355771.USD","LU1983299246.USD","IBB","LU1057294990.SGD","LU1061106388.HKD","BK4139","UUP","IE00B4R5TH58.HKD","PJP","LU2112291526.USD","LU1571399168.USD","LU2242646821.SGD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0868494617.USD","BK4533","IE00B2B36J28.USD","BK4588","LU2242652126.USD","SG9999001440.SGD","BK4599","TBXU","IE0002141913.USD","AMGN","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660416851","title":"藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2660416851","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660416851?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:48","pubTimestamp":1787104101,"startTime":"0","endTime":"0","summary":"湘雅二医院方面向澎湃新闻表示，院方确有发该“协办函”。据此次公布的协办函，对几家涉事药企的处理决定颇为严厉。近年来，医药代表违规已不仅是行业道德问题，而是监管重点。此次湘雅二医院将企业列入购销负面清单，正是医院端落地上述政策的缩影。湘雅二医院相关负责人表示，自国家在2020年底建立医药代表备案制度，医院就积极响应国家政策，并不断完善内部制度和执行流程。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787103396417327872","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IBB","BK4588","BK4581","LU0320765992.SGD","AMGN","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1571399168.USD","LU0109394709.USD","LU2242652126.USD","BK4534","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","BBH","LU2089984988.USD","BK4566","LU2468319806.SGD","LU1057294990.SGD","688578","BK4533","BK0239","TBXU","BIB","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4599","LU0889565916.HKD","IE0009355771.USD","BK4585","PJP","LU1983299246.USD","IBBQ","IE00B2B36J28.USD","LU0868494617.USD","SG9999001440.SGD","IE0002141913.USD","LU0122379950.USD","LU1061106388.HKD","PBE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安進將終止與其研究合作及許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192416297?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4588","BK4566","LU2242646821.SGD","IE00BJJMRZ35.SGD","AMGN","IE00BFTCPJ56.SGD","PBE","BK4534","LU0289739699.SGD","LU1571399168.USD","SG9999001440.SGD","LU0868494617.USD","LU1023059063.AUD","IE0009355771.USD","LU2089984988.USD","LU1057294990.SGD","LU0109394709.USD","BK4533","IE0002141913.USD","BK4599","LU2112291526.USD","TBXU","LU2242652126.USD","LU2468319806.SGD","IBB","IE00B4R5TH58.HKD","LU1061106388.HKD","BK4139","PJP","BK4539","BIB","IBBQ","BK4581","LU1983299246.USD","TCRX","LU0122379950.USD","BK4585","LU0058720904.USD","BBH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491619","title":"吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491619","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660491619?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 02:16","pubTimestamp":1787076999,"startTime":"0","endTime":"0","summary":"• 联邦法院禁令阻止了吉利德关键HIV药物的海外进口。\n• 强劲的基础业务营收增长与上调业绩指引提振了市场乐观情绪。\n• 肿瘤领域的战略投资及机构看涨期权活动的活跃支撑了股价的上涨势头。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262115765-market-movers-gild-20260818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","IBB","MEDI","SG9999015952.SGD","GILD","LU1061106388.HKD","LU1934455863.HKD","BK4532","LU1023059063.AUD","BK4550","LU2087621335.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU0965509101.SGD","LU2324357040.USD","IE00B7SZLL34.SGD","LU0965508806.USD","BK4583","LU1037948897.HKD","TBXU","LU0320765992.SGD","LU1430594728.SGD","LU0289739699.SGD","LU0109394709.USD","LU1037948541.HKD","SG9999015978.USD","IE00B19Z3581.USD","SG9999015986.USD","BMED","LU0114720955.EUR","BK4585","LU1066053197.SGD","LU1778281490.HKD","IE00BZ1G4Q59.USD","BK4566","LU1674673428.USD","IE00B3T34201.USD","LU2112291526.USD","LU1674673691.USD","BK4578","LU2089984988.USD","BIB","LU0823416689.USD","IBBQ","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU1839511570.USD","LU1571399168.USD","BBH","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332334","title":"EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332334","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 22:15","pubTimestamp":1786976114,"startTime":"0","endTime":"0","summary":"BUZZ-EyePoint股价料将创下历史最大跌幅，因其一款实验性眼科药物未能达到后期临床试验目标最新动态8月17日-**EyePoint公司（EYPT.O）股价暴跌71%至4.17美元，有望创下有史以来最大单日跌幅，并跌至2025年4月以来的最低点**这家药物开发商表示，其实验性眼科药物Duravyu在针对湿性年龄相关性黄斑变性（视力丧失的主要原因之一）患者开展的晚期临床试验中，未能达到主要目标","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4007","LU0823434740.USD","EYPT","LU0320765992.SGD","REGN","BBH","IBBQ","LU0289739699.SGD","TBXU","LU1917777945.USD","LU2023250504.SGD","LU0114720955.EUR","LU2237438978.USD","IBB","LU0882574055.USD","LU0109394709.USD","BK4139","LU2362541513.USD","LU1974910355.USD","LU2362541273.HKD","BK4585","BK4588","LU2089984988.USD","LU0823434583.USD","LU2468319806.SGD","LU2362540622.SGD","LU0053666078.USD","LU0058720904.USD","LU2106854487.HKD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848445","title":"EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848445","media":"路透中文","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848445?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:14","pubTimestamp":1786965255,"startTime":"0","endTime":"0","summary":"EyePoint公司未能证明Duravyu在保护视力方面不比Eylea明显逊色。而在接受Eylea治疗的患者中，未出现此类情况。EyePoint的股价在早盘交易中跌至4.16美元。EyePoint计划于2027年上半年向美国FDA提交批准申请，具体取决于预计于今年晚些时候公布的第二项晚期临床试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","LU0823434583.USD","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","LU2089984988.USD","IBBQ","BBH","BK4588","LU1917777945.USD","LU0889565916.HKD","LU0823416689.USD","LU2106854487.HKD","REGN","LU1974910355.USD","LU0109394709.USD","EYPT","LU2362541513.USD","LU2362541273.HKD","LU0053666078.USD","LU0823434740.USD","BK4585","LU2237438978.USD","LU2468319806.SGD","BK4139","BK4007","LU2023250504.SGD","LU2362540622.SGD","OTLK","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101358","title":"巴克萊上調安進目標價至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101358?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 11:05","pubTimestamp":1786935953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0889565916.HKD","LU0109394709.USD","AMGN","IE00B4R5TH58.HKD","LU0122379950.USD","LU1571399168.USD","PBE","LU2112291526.USD","BK4533","LU0058720904.USD","LU2468319806.SGD","UUP","LU2089984988.USD","PJP","BK4588","IBB","LU0320765992.SGD","LU1057294990.SGD","UDN","LU2242652126.USD","LU0289739699.SGD","LU0868494617.USD","LU1061106388.HKD","BK4581","SG9999001440.SGD","TBXU","IE00BFTCPJ56.SGD","BK4566","LU1983299246.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4139","LU2242646821.SGD","BBH","BIB","IBBQ","IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4599","BK4534","BK4585","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659400001","title":"Assembly股價上漲，因季度營收超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2659400001","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659400001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 23:25","pubTimestamp":1786721141,"startTime":"0","endTime":"0","summary":"BUZZ-Assembly股价上涨，因季度营收超出预期8月14日-** 药物研发公司Assembly Biosciences（ASMB.O）股价上涨4.6%，报31.32美元** ASMB第二季度与吉利德（GILD.O）合作研究的收入为1340万美元，高于去年同期的960万美元** 据LSEG数据显示，分析师此前平均预期营收为860万美元** 公司表示，营收增长包括针对吉利德合作项目下未来活动最新预估所作的510万美元补足调整** 报告显示第二季度每股亏损20美分，而市场预期为每股亏损65美分** 计入当日涨幅后，该股年初至今累计上涨11.8%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL4S44B103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4583","LU0058720904.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU0965509101.SGD","IE00BSNM7G36.USD","BBH","LU2112291526.USD","LU0965508806.USD","LU1061106388.HKD","BK4566","LU2468319806.SGD","SG9999015952.SGD","LU0861579265.USD","LU1037948541.HKD","LU2324357040.USD","LU1839511570.USD","LU0889565916.HKD","LU2087621335.USD","ASMB","LU1066051498.USD","BK4585","LU0114720955.EUR","MEDI","IE00B19Z3581.USD","TBXU","BK4532","LU1037948897.HKD","SG9999015945.SGD","LU0234570918.USD","GILD","IBBQ","IE00B3T34201.USD","LU1934455277.USD","SG9999015986.USD","LU1066053197.SGD","BK4139","BK4568","IBB","LU0122379950.USD","LU0289739699.SGD","LU0965509283.SGD","LU0109394709.USD","TMED","BK4588","IE00B19Z3B42.SGD","BK4578","BIB","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659710130","title":"庫利南股價上漲，因其肺癌藥物達到晚期臨床試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2659710130","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659710130?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 17:40","pubTimestamp":1786614009,"startTime":"0","endTime":"0","summary":"BUZZ-库利南股价上涨，因其肺癌药物达到晚期临床试验目标8月13日-** 库利南治疗公司（Cullinan Therapeutics）CGEM.O的股价在盘前交易中上涨6%，至20.77美元** 库利南公司表示，其实验性抗癌药物zipalertinib与铂类化疗联合使用，在晚期临床试验中达到了改善无进展生存期的主要目标 (link)** 与单独化疗相比，该联合疗法显著延缓了既往未接受过治疗、携带","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4S44A0QI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0889565916.HKD","CANC","BBH","IE0009355771.USD","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0109394709.USD","IDNA","IE0002141913.USD","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658465479","title":"MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項","url":"https://stock-news.laohu8.com/highlight/detail?id=2658465479","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658465479?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 05:18","pubTimestamp":1786483082,"startTime":"0","endTime":"0","summary":"BUZZ-MacroGenics股价上涨，因吉利德支付了1000万美元的里程碑款项8月11日-** 药物开发商MacroGenics（MGNX.O）的股价在盘后交易中上涨3.8%，至4.07美元** 该公司表示，根据其与吉利德（GILD.O）就一项临床前双特异性项目（一种癌症疗法）达成的许可协议，已收到1000万美元的里程碑付款** 根据2022年签署的合作协议，MacroGenics与吉利德正在推进三个项目：处于临床阶段的抗癌疗法MGD024，以及两个处于临床前阶段的双特异性项目** MGNX仍有资格获得最高约16亿美元的额外开发、监管及商业里程碑付款** 今年以来，该公司股价已翻了一番多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4481IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMED","MEDI","LU0965508806.USD","LU1066051498.USD","BK4566","LU1430594728.SGD","IE00B7SZLL34.SGD","LU1571399168.USD","LU2468319806.SGD","BK4139","BK4578","BMED","LU1778281490.HKD","BIB","LU2087621335.USD","LU1674673428.USD","BK4532","BBH","LU1585245621.USD","LU1934455863.HKD","IBB","MGNX","IE00BKVL7J92.USD","LU0114720955.EUR","LU0965509101.SGD","LU1023059063.AUD","LU0234570918.USD","LU0058720904.USD","GILD","BK4585","LU0882574055.USD","SG9999015986.USD","SG9999015978.USD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1839511570.USD","LU1934455277.USD","LU2089984988.USD","SG9999015952.SGD","LU1674673691.USD","LU2324357040.USD","IE0002270589.USD","IE00BSNM7G36.USD","BK4550","TBXU","IBBQ","SG9999015945.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658591102","title":"數據簡報-全球製藥企業斥資數十億以擴大在美業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2658591102","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658591102?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:59","pubTimestamp":1786463961,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美业务更新了第18段中关于百健生产工厂的数据路透8月11日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。这家制药公司宣布将投资 6.5 亿美元 ，以扩大其位于波多黎各洪科斯工厂的药品生产规模，此举预计将创造近 750 个就业岗位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S448167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","LU1941712348.USD","LU2491050071.SGD","LU1032466523.USD","GB00BDT5M118.USD","IE00B3T34201.USD","LU2129689514.USD","LU1506573853.SGD","BIIB","MHIP","LU0882574055.USD","LU1988902786.USD","SG9999015358.SGD","SGXZ99366536.SGD","MEDX","SG9999015952.SGD","IE0004445015.USD","LU1585245621.USD","LU2211815571.USD","LU0823434740.USD","LU0942090050.USD","BK4581","IE00B3PB1722.GBP","SG9999015978.USD","LU0124676726.USD","LU2023250330.USD","LU1629891620.HKD","SGXZ80539844.SGD","IE00BBT3K403.USD","LU0053666078.USD","LU2237438978.USD","LU0868494708.USD","LU1430594728.SGD","LU1974910355.USD","LU2430703251.USD","IE000MB6IJN5.SGD","LU2596442595.SGD","LU0980610538.SGD","LU1069344957.HKD","LU2491050154.USD","LU2089284900.SGD","IBB","BK4007","IE00BJJMRY28.SGD","LU2168564222.USD","IE00BK4W5L77.USD","LU0208291251.USD","LU0965509283.SGD","LU1868836591.USD","LU1917777945.USD","LU2357627491.SGD","LU2552382058.USD","LU1699723380.USD","LU0320765646.SGD","LU0820561909.HKD","LU2063271972.USD","LU2750360997.AUD","LU0057025933.USD","LU1064131342.USD","LU2491049909.HKD","LU0098860793.USD","LU1712237335.SGD","LU0256863902.USD","LU2360106947.USD","LU0210528500.USD","LU1116320901.HKD","BK4592","LU0079474960.USD","LU0238689110.USD","LU2111349929.HKD","LU0203345920.USD","LU0006306889.USD","LU0994945656.USD","LU0158827781.USD","LU2433249047.HKD","BK4559","SG9999013999.USD","LU1670711040.USD","LLYZ","LU1244550494.USD","SG9999011175.SGD","IE00B775H168.HKD","LU0432979614.USD","LU0477156953.USD","LU2456880835.USD","SG9999001176.USD","FHLC","IE00B19Z3581.USD","LU1267930730.SGD","LU2112291526.USD","LU0320765059.SGD","LU0786609619.USD","BK4532","LU1035775433.USD","LU1979441026.SGD","LU1496350502.SGD","IE00BKDWB100.SGD","IE0000B7K699.USD","LU0122379950.USD","LU1778281490.HKD","LU1366192091.USD","IE00BFXG1179.USD","LU2756315318.SGD","LU0237698245.USD","LU1720051108.HKD","LU1551013425.SGD","AMGN","BMED","IE00BJT1NW94.SGD","LU0672654240.SGD","LU1023059063.AUD","LU1983299246.USD","LU2264538146.SGD","LU1323610961.USD","LU0114720955.EUR","LU0456855351.SGD","LU0965509010.AUD","LU0211327993.USD","LU0321505439.SGD","LU2461242641.AUD","BK4533","LU0964807845.USD","IE00BZ1G4Q59.USD","SG9999014542.SGD","LU2347655073.USD","LU0738911758.USD","IE0002141913.USD","LU2237443622.USD","LU2265009873.SGD","LU0912757837.SGD","IE000F7OJYX1.SGD","TBXU","MEDI","LU0133085943.USD","LU0466842654.USD","LU2023250843.SGD","XLV","LU1934455194.USD","LU0320765489.SGD","LU0211328371.USD","IE0002270589.USD","LU2430703095.HKD","LU0106261372.USD","LU2756315664.SGD","LU2087625088.SGD","LU2125154935.USD","LU0648001328.SGD","IE00BLSP4452.SGD","LU0689626769.HKD","LU0203202063.USD","SG9999001176.SGD","IE00B4R5TH58.HKD","PFE","HRTS","LU2552382215.SGD","LU1121112475.USD","LU0310799852.SGD","IE00BN8TJ469.HKD","IE0001KFT4U8.USD","LU1069347547.HKD","LU1894683348.USD","IE00BGHQF631.EUR","CURE","LU2357305700.SGD","IE00BDGV0183.EUR","LU0162691827.USD","IE00B42XCP33.USD","IE0005OL40V9.USD","SG9999015945.SGD","IBBQ","LU1221951129.SGD","LU0234570918.USD","LU1261432733.SGD","LU2505996681.GBP","IE00BLSP4239.USD","LU1674673691.USD","LU1267930573.SGD","SG9999014559.SGD","LU0661504455.SGD","LU1670628061.USD","LU1935042991.SGD","LU1670710588.SGD","LU2023250504.SGD","AZNH","TRUH","LU2468319806.SGD","SG9999002224.SGD","GLAM","IE00B19Z9Z06.USD","LU2242646821.SGD","BK4504","SG9999002232.USD","LU0345769128.USD","LU0265550359.USD","LU1623119135.USD","SGXZ51526630.SGD","LU1093756325.SGD","LU1232071149.USD","LU0868494617.USD","LU1228905037.USD","LU0225283273.USD","IE00BKVL7J92.USD","LU2746668461.USD","JDOC","LU0072461881.USD","BK7501","LU2168563687.JPY","LU2417539215.USD","BK4534","IE00B1XK9C88.USD","LU0820562030.AUD","LU1868836914.USD","SG9999015986.USD","LU1934455863.HKD","LU0882574139.USD","IE000WAW04H5.SGD","LU2125909247.SGD","LU2602419157.SGD","LU1127390331.HKD","LU0306807586.USD","LU1066051811.HKD","SGXZ31699556.SGD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU1061106388.HKD","LU1066053197.SGD","VHT","LU1291159041.SGD","BK4566","LU1868836757.USD","LU0859254822.USD","LU1883839398.USD","BK4599","LU0471298694.HKD","GDOC","LU0708995401.HKD","TMED","LU2360032135.SGD","LU0385154629.USD","LU0726765562.USD","IE0034235303.USD","LU0795875086.SGD","LU2471134523.USD","LU0097036916.USD","IE00B19Z9P08.USD","IE000M9KFDE8.USD","WDNA","LU0426417589.USD","LU0708994859.HKD","LU2168564065.EUR","LU0058720904.USD","LU2125909593.SGD","LU2505996509.AUD","BK4139","LU1804176565.USD","SG9999003800.SGD","LLY","LU0395794307.EUR","LU2237443978.SGD","IE00BN29S564.USD","LU1280957306.USD","LU2129689605.HKD","SGXZ81514606.USD","LU1496350171.SGD","IE00BFSS8Q28.SGD","LU1720051017.SGD","LU2168564495.EUR","FTXH","LU2213496289.HKD","LU1670710661.SGD","LU0417517546.SGD","LU0234572021.USD","PJP","LU0174119429.USD","LU0289739343.SGD","LU0128525929.USD","IE00BJLML261.HKD","LU0354030511.USD","LU2237443465.HKD","LU1548497426.USD","LU1923622614.USD","LU1868837136.USD","BIB","IE00B19Z3B42.SGD","LU0965509101.SGD","ELIS","BMY","IE00BVYPNW00.USD","LU1196500208.SGD","LU1043141396.HKD","LU2324357040.USD","IE00B2B36J28.USD","IE00B7KXQ091.USD","LU2361044949.HKD","RXL","CANC","LU0265550946.USD","IE00BFSS7M15.SGD","BK4568","AZN","LU1718418525.SGD","LU1941712264.USD","LU0861579265.USD","LU2237443549.SGD","LU0943347566.SGD","LU1057294990.SGD","LU0640476718.USD","LU1244550577.SGD","LU2087621335.USD","LU1732799900.SGD","IHE","LU2361045086.USD","LU1670627923.USD","LU1145028129.USD","LLII","LU0792757196.USD","LU0170899867.USD","LU1674673428.USD","BBH","LU0545039389.USD","BK4588","BK7067","LU0345770993.USD","LU0029864427.USD","IE000SO60NU8.SGD","LU0787776722.HKD","LU2592432038.USD","LU0472753341.HKD","LU0683600562.USD","LU1162221912.USD","LU0198837287.USD","LU0553294199.USD","LU0965508806.USD","LU2108987350.USD","LU0109391861.USD","LU0471298777.SGD","LU2237443382.USD","BK4550","LU0889566641.SGD","LU0345770308.USD","IE00BVYPNV92.GBP","ELIL","LU1914381329.SGD","LU2089984988.USD","PPH","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0130517989.USD","IYH","IE00B894F039.SGD","IE00BWXC8680.SGD","LLYX","LU0985320562.USD","04332","LU2896262040.SGD","SG9999014898.SGD","LU1066051498.USD","LU0225284248.USD","SG9999014567.USD","LU1066051225.USD","LU1035773651.USD","SG9999015341.SGD","LU1221951046.USD","BK4578","IE00BK4W5M84.HKD","LU1032955483.USD","LU2237443895.HKD","LU1116320737.USD","LU2462157665.USD","LU2129689431.USD","LU0203201768.USD","LU2487616109.SGD","LU1989771016.USD","LU0823434583.USD","LU0096364046.USD","LU1571399168.USD","LU2403377893.USD","BK4583","BK7511","LU0949170772.SGD","LU0210536198.USD","LU1201861249.SGD","LU0316494557.USD","SG9999017495.SGD","LU0266013472.USD","LU0256863811.USD","LU2089283258.USD","BK4516","LU2028103732.USD","IE0004445239.USD","GILD","LU0985481810.HKD","LU1839511570.USD","LU0689472784.USD","LU1267930813.SGD","ABBV","LU0211331839.USD","LU2746668974.SGD","LU1829250122.USD","LU0354030438.USD","LU2106854487.HKD","OZEM","LU1868837300.USD","LU0306806265.USD","LU1003077747.HKD","LU1732800096.USD","PBE","LU0353189763.USD","SG9999014880.SGD","IXJ","LU0889565916.HKD","LU2430703178.SGD","LU2750360641.GBP","LU2361044865.SGD","LU1093756168.USD","LU0070217475.USD","LU0069063385.USD","LU0353189680.USD","LU0070302665.USD","THNR","AGNG","IE00BSNM7G36.USD","LU0820561818.USD","LU2125154778.USD","LU0795875169.SGD","LU0158827948.USD","LU1228905540.USD","SG9999001440.SGD","IE00BKPKM429.USD","LU1894683264.USD","LU0823416689.USD","SG9999014906.USD","IE0009355771.USD","LU2471134952.CNY","BK4585","LU1934455277.USD","LU2471134796.USD","LU0323591593.USD","LU0310800379.SGD","LU1244550221.USD","LU2242652126.USD","LU1059921491.USD","LU2023251221.USD","LU0109394709.USD","SG9999018857.SGD","IE000BZT7R73.USD","LU2552382132.HKD","LU2168564149.EUR","CSL.AU","LU2236285917.USD","LU2133065610.SGD","LU1989772923.USD","SG9999018865.SGD","LU0289961442.SGD","LU2471134879.HKD","PAWZ","LU1989772840.SGD","IE00B7SZLL34.SGD","LU0130102774.USD","LU1074936037.SGD","LU2347655156.SGD","LU1551013342.USD","LU1043141123.HKD","IE00BJJMRX11.SGD","LU1670711123.USD","SG9999014575.USD","IE00B1BXHZ80.USD","LU0511384066.AUD","LU0225771236.USD","LU1037948541.HKD","MRK","IE00B4JS1V06.HKD","LU2462591350.SGD","LU0320765992.SGD","LU1267930490.SGD","ILDR","LU1929549753.HKD","LU0094547139.USD","SG9999014914.USD","LU0426412945.USD","LU1814569148.SGD","LU1037948897.HKD","LU0545562505.USD","LU2271345857.HKD","SGXZ57979304.SGD","LU0345769631.USD","JNJ","LU0321505868.SGD","LU0267386448.USD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658391156","title":"Tango因季度虧損額超出預期而股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2658391156","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658391156?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:19","pubTimestamp":1786461555,"startTime":"0","endTime":"0","summary":"BUZZ-Tango因季度亏损额超出预期而股价下跌8月11日-** 药物研发公司Tango TherapeuticsTNGX.O股价下跌3.3%，报26.75美元** 据LSEG数据显示，该公司报告第二季度每股亏损37美分，而分析师平均预期为每股亏损31美分** TNGX报告称，截至2026年6月30日的三个月内未产生合作收入，原因是与吉利德GILD.O的合作关系及研发活动已终止** 该公司202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4T44814U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","TNGX","BK4585","IDNA","LU0889565916.HKD","LU0114720955.EUR","BIB","BK4532","IE00BJJMRZ35.SGD","LU1778281490.HKD","LU2468319806.SGD","IE0002270589.USD","TMED","IE00BZ1G4Q59.USD","BK4588","LU1037948897.HKD","LU2089984988.USD","MEDI","IE00B2B36J28.USD","LU1674673428.USD","LU2087621335.USD","LU0861579265.USD","IE00B4R5TH58.HKD","LU1066051498.USD","IE00B19Z3581.USD","LU1934455277.USD","LU0109394709.USD","BK4583","SG9999015952.SGD","CANC","LU0320765992.SGD","IBB","GILD","IE00BJT1NW94.SGD","BBH","IE00B7SZLL34.SGD","LU0965508806.USD","RVMD","LU1066053197.SGD","BK4139","LU2324357040.USD","LU0965509010.AUD","LU0289739699.SGD","TBXU","LU1674673691.USD","IE0009355771.USD","LU0234570918.USD","LU1934455863.HKD","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975709","title":"Truist因Revolution Medicines在肺癌研發管線方面的潛力而上調其目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975709","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975709?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 19:42","pubTimestamp":1786448532,"startTime":"0","endTime":"0","summary":"BUZZ-Truist因Revolution Medicines在肺癌研发管线方面的潜力而上调其目标价8月11日-** 券商Truist Securities将Revolution Medicines（RVMD.O）的目标股价从210美元上调至231美元** 维持“买入”评级** 指出elironrasib和zoldonrasib近期已推进至一线非小细胞肺癌（NSCLC）的晚期临床试验，这进一步巩","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4480SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0889565916.HKD","CANC","BBH","IE0009355771.USD","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0109394709.USD","IDNA","IE0002141913.USD","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161961","title":"市值超4800億元的藥企股價漲逾4%: 這款「癌王」突破療法要來中國了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658161961?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","688235","IE00BJT1NW94.SGD","PTH","KURE","BBH","IE00B2B36J28.USD","LU1978683503.SGD","BK1588","BK4141","LU0889565916.HKD","LU1861215975.USD","LU2357305700.SGD","LU1720051108.HKD","IE00BZ199S13.USD","LU1854103824.USD","IE0009355771.USD","BK4588","LU1720051017.SGD","BK1583","LU0109394709.USD","LU2360107325.USD","LU1548497426.USD","BK4605","LU1770034418.SGD","BK4512","LU0588546209.SGD","LU0348723411.USD","LU1854104046.USD","LU1983260115.SGD","IE0009354923.USD","IDNA","LU1861219969.SGD","LU0124384867.USD","ON","IE0002141913.USD","IE00BFTCPJ56.SGD","06160","CANC","IE00BJJMRZ35.SGD","LU0724618433.USD","LU2298322129.HKD","LU1861214812.USD","LU0320765992.SGD","LU1251922891.USD","BK4139","IE00BD6J9T35.USD","BK0239","RVMD","IE00BFMHRM44.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股異動 | 百濟神州(06160)早盤升逾4% 與Revolution Medicines達成臨床合作 將加快RAS賽道開發進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658965691?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","LU0109394709.USD","BK1161","IE00BFTCPJ56.SGD","ONC","LU1770034418.SGD","BK4526","LU1251922891.USD","BK4139","LU1969619763.USD","PTH","06160","IE0002141913.USD","IDNA","BK0239","BK1500","LU1719994722.HKD","BK1588","BK4585","LU0320765992.SGD","LU0828237510.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU2328871848.SGD","LU0889565916.HKD","BK4588","IE00B2B36J28.USD","LU0588546209.SGD","IE00B4R5TH58.HKD","BBH","IE0009354923.USD","CANC","RVMD","BK1583","LU1303224171.USD","VXUS","IE0009355771.USD","KURE","LU0228659784.USD","688235","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百濟神州（06160）盤初漲3.94% 與安進聯合開發及商業化的安泰適正式投入臨床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658196566?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2242652126.USD","IE0002141913.USD","PJP","BK4139","BK1583","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1061106388.HKD","SG9999001440.SGD","TBXU","BIB","LU1969619763.USD","BBH","LU0307460666.USD","LU2089984988.USD","BK4526","BK4533","LU1023059063.AUD","LU2112291526.USD","LU2468319806.SGD","BK4534","LU0828237510.HKD","LU1983299246.USD","IE00B2B36J28.USD","BK1588","LU0228659784.USD","LU0122379950.USD","06160","BK4599","BK4588","BK1161","IBBQ","LU1571399168.USD","BK4585","LU2242646821.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","KURE","LU0588546209.SGD","BK4566","ONC","BK1500","IBB","688235","AMGN","LU0289739699.SGD","PBE","LU0109394709.USD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":187,"code":"91000000","status":"200"}]}}